Tevogen Bio Holdings Inc. (TVGN)
Automate Your Wheel Strategy on TVGN
With Tiblio's Option Bot, you can configure your own wheel strategy including TVGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TVGN
- Rev/Share 0.0022
- Book/Share -0.0515
- PB -17.2692
- Debt/Equity -0.7966
- CurrentRatio 0.255
- ROIC 17.071
- MktCap 174811726.0
- FreeCF/Share -0.0724
- PFCF -13.0944
- PE -5.2498
- Debt/Assets 1.7699
- DivYield 0
- ROE 4.1504
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TVGN | D. Boral Capital | -- | Buy | -- | $10 | March 4, 2025 |
News
Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
Published: September 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared the risk-adjusted net present value (rNPV) estimate of $9 billion to $11 billion for TVGN-489, an allogeneic precision T cell therapy and the first clinical-stage product from its proprietary ExacTcell™ platform. TVGN-489 is being developed for the treatment of SARS-CoV-2 infection in high-risk vulnerable patients and for Long-COVID in patients with evidence of a persistent viral reservoir.
Read More
Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas
Published: September 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared asset value and potential forecast for the Company's pipeline product, TVGN 930, for treatment of non-solid tumor malignancies stemming from Epstein-Barr Virus (EBV).
Read More
Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today updated investors of its significant internally developed assets, which under U.S. GAAP accounting rules are not reflected on the Company's balance sheet, yet represent substantial long-term value. Tevogen will provide detailed information and valuation of these assets in the coming days.
Read More
Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity
Published: August 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its appreciation to Yale University for recognizing Founder and CEO Dr. Ryan Saadi, MPH '95, and the Company's mission of health equity.
Read More
Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions
Published: August 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced an update on institutional ownership of the Company's outstanding common stock, as reported by institutional investment managers on Form 13F filed with the Securities and Exchange Commission (SEC).
Read More
Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma
Published: August 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), announced today that it has been named in BINJE's BEST Health Care 2025: Companies, Organizations and Service Providers. BINJE, a media outlet covering business and politics across New Jersey, highlighted Tevogen Bio's Founder and CEO, Ryan Saadi, MD, MPH, for his commitment to health equity and innovation in sustainable biopharma.
Read More
REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
Published: August 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Includes $36 million line of credit and potential $14 million private placement WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, following the recent elimination of $94.9 million in balance sheet liabilities, has entered into a definitive agreement for up to $50 million in financing.
Read More
Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum
Published: August 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN) announced its financial results for the fiscal quarter ended June 30, 2025, and filed its Form 10-Q with the Securities and Exchange Commission (“SEC”), highlighting improved operational efficiency.
Read More
Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected
Published: August 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), today issued the following statement from Ryan Saadi, M.D., M.P.H., Founder and CEO.
Read More
Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
Published: August 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its artificial intelligence initiative, Tevogen.AI, is expanding its collaboration with Microsoft (Nasdaq: MSFT) and Databricks, to build the beta version of its foundational PredicTcell model.
Read More
Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), reiterates investor confidence and estimated asset value over $10 billion.
Read More
REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line revenue forecast for its specialty care pipeline, projecting nearly $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $18 billion and $22 billion. This forecast reflects the company's unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.
Read More
REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today released a letter to stockholders.
Read More
REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
Published: August 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced an update on institutional ownership of the Company's outstanding common stock, as reported by institutional investment managers on Form 13F filed with the Securities and Exchange Commission (SEC).
Read More
Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
Published: August 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its artificial intelligence initiative, Tevogen.AI, is expanding its collaboration with Microsoft (Nasdaq: MSFT) and Databricks, to build the beta version of its foundational PredicTcell model.
Read More
Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
Published: August 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today released a letter to stockholders.
Read More
Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion
Published: August 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced that it expects to receive $1 million in grant funding to advance Tevogen.AI, its artificial intelligence–powered drug discovery and development program.
Read More
Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the Company's significant insider ownership of outstanding common stock, as most recently reported on July 10, 2025, on Form 8-K filed with the Securities and Exchange Commission.
Read More
Tevogen.AI Applauds U.S. Government's AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today welcomes the White House's release of “Winning the Race: America's AI Action Plan”, issued July 23, 2025. The Company applauds the federal government's emphasis on establishing domain-specific standards, regulatory sandboxes (aka AI Centers of Excellence), and stakeholder convenings led by The National Institute of Standards and Technology to build trust, governance, and productivity in healthcare AI.
Read More
Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
Published: July 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., July 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced today that the International Bureau of the World Intellectual Property Organization (WIPO) has published its international patent application (Publication No. WO 2025/129197) titled, "Systems and Methods for Predicting Immunologically Active Peptides with Machine Learning Models."
Read More
Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the signing of a letter of intent to lease a 17,428-square-foot facility in New Jersey. The facility, formerly occupied by Pfizer and Cordis, a previous division of Johnson & Johnson, should support the Company's cell therapy manufacturing operations.
Read More
Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch
Published: July 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., July 16, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that following the completion and deployment of the alpha version of PredicTcell™, a proprietary AI-driven target discovery platform, the Company now plans to expand Tevogen.AI to include patient data against identified targets.
Read More
Tevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs
Published: July 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its artificial intelligence initiative, Tevogen.AI, in collaboration with Microsoft (Nasdaq: MSFT) and Databricks, has successfully built the alpha version of its foundational PredicTcell™ model.
Read More
Tevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation
Published: July 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the completion and official opening of its fully functional, newly expanded corporate headquarters in Warren, New Jersey. The build-out and first-year operating costs were personally gifted by Founder and Chief Executive Officer Ryan Saadi, M.D., M.P.H., resulting in no expense to the Company or its shareholders.
Read More
Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters
Published: June 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that founder and Chief Executive Officer, Ryan Saadi, M.D., M.P.H., has personally contributed $500,000 towards the build-out and first-year operating costs of Tevogen's new corporate headquarters in Warren, New Jersey.
Read More
Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives
Published: June 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
R&D and cross-functional operations will be centralized in a single location to enhance collaboration and operational efficiency. Tevogen.AI, strengthened by its partnership with Microsoft, continues to expand.
Read More
Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships
Published: May 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today provided stockholders with a detailed overview of its artificial intelligence initiative, Tevogen.AI™.
Read More
Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow
Published: May 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced a planned expansion of TVGN 489's target population to include patients 65 and older. As previously reported in October 2024, the top-line revenue forecast for the specialty care pipeline was projected at nearly $1 billion in its launch year, with a cumulative five-year estimate ranging between $18 billion and $22 billion. This anticipated expansion aims to broaden the market potential of Tevogen's specialty pharmaceuticals. An updated forecast and the risk adjusted net present value (rNPV) will be provided to reflect the …
Read More
Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that it will provide several updates to stockholders in advance of the Company's upcoming Annual Meeting of Stockholders scheduled for June 23, 2025. These updates will provide content regarding the Company's innovative business model and strategic growth initiatives, which management believes position the Company strongly for future value realization.
Read More
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN). As the biopharma industry faces increasing competition from international markets and an evolving regulatory landscape, Tevogen Bio's innovative business model positions it as a potential leader in the shift towards cost-efficient, value-driven healthcare.
Read More
About Tevogen Bio Holdings Inc. (TVGN)
- IPO Date 2022-01-05
- Website https://tevogen.com
- Industry Biotechnology
- CEO Ryan H. Saadi M.P.H,
- Employees 18